Business Wire

NY-UNIFRAX

7.4.2021 13:02:12 CEST | Business Wire | Press release

Share
Unifrax Introduces New Catalysis Product Eco-lytic™ — a Cleaner, Lower Weight, and More Efficient Solution for Reducing Vehicle Emissions

Unifrax , the leading manufacturer of high-performance specialty materials, today introduced a new, nano-structured alumina catalyst support technology for the transportation market – Eco-lytic™ by Unifrax . Housed within a vehicle’s catalytic converter, the Eco-lytic catalyst support fiber is designed to replace the existing catalytic converter or add to existing systems in order to enhance emission reduction, consume fewer precious metals and raw materials, and drive lower energy usage through vehicle weight reduction. The solution is designed to help prolong a cleaner engine life and enable vehicle manufacturers to meet increasingly stringent environmental, social, and governance (ESG) standards and regulations, while providing considerable cost savings as the market transitions to electric vehicles (EVs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005247/en/

Eco-lytic is currently in advanced testing with several global automakers. Preliminary results suggest the solution can reduce the mass of catalyst support media by up to 80 percent and lower platinum group metal loading by up to 40 percent compared to traditional systems. This results in increased efficiency due to faster light-off of catalytic performance. Unifrax will have commercial production capability on-line in late 2021.

“The transportation industry is going through an incredible transformation – vehicle manufacturers and regulators are focusing efforts on reducing greenhouse gas emissions and transitioning to electric or plug-in hybrid vehicles. This transition will not happen overnight, and the industry is in desperate need of nearer-term solutions to help bridge the sector’s transition to a greener footprint. Eco-lytic is that solution and the step change we need today,” said Chad Cannan, Senior Vice President of Research and Development, Unifrax. “Eco-lytic is poised to be a game changer for any conventional engine, large or small, mobile or stationary. Our product is designed to enhance emissions reductions, reduce the need for precious raw materials, extend cleaner engine lives and help drive a more sustainable carbon footprint through vehicle weight reduction.”

Eco-lytic’s flexible structure not only offers efficiency and cost savings benefits, it also provides transportation industry partners and manufacturers with unique packaging options. Unifrax has the ability to tailor the Eco-lytic product to meet the needs of individual partners through custom shapes and sizes to fit into locations where existing technologies cannot.

“Unifrax continues to pursue its mission to make the world a greener, cleaner, and safer place. We have been working to support the industry’s transition to EVs through a robust battery and technology solution portfolio that includes: our recently announced proprietary anode technology SiFab™, which drives significantly higher energy density in lithium ion batteries, our AGM separator materials, our large format lithium ion glass separators, our interstitial thermal runaway barriers, our battery compartment fire protection systems and now Eco-lytic,” said John Dandolph, President and CEO, Unifrax. “Eco-lytic provides an exciting bridge to reduce catalytic converter weights and costs, reduce the use of precious metals and raw materials, and minimize the environmental impact of conventional engines as the industry transitions to EVs. As such, Eco-lytic is a unique and proprietary solution which opens the door to a new age of emission control aligned with our mission at Unifrax.”

Building on Unifrax’s deep history of fiber-based technology and manufacturing, Eco-lytic is Unifrax’s first step into catalytic support. Unifrax, the inventor of specialty ceramic fibers, has a track record of 75+ years of developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, including electric vehicles, aerospace, and chemical processing.

Unifrax will be available during SAE’s WCX Digital Summit , April 13–15, 2021, to discuss the Eco-lytic technology with interested attendees. For more information on Eco-lytic, visit www.unifrax.com .

About Unifrax

Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn , and Facebook .

About Clearlake

Founded in 2006, Clearlake Capital Group, L.P. is an investment firm operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are industrials, technology, and consumer. Clearlake currently has approximately $35 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye